Pancreatic Cancer Research

ResearcherDalian Medical UniversityNo recent work listed

Na Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0404-6431; OpenAlex author ID A5100368060. Sources: OpenAlex.

Their work

Papers
2
Trials
0
Grants
0
Labs led
0
Collaborators
7
Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper

Papers 2

  1. An oleanolic acid derivative, K73-03, inhibits pancreatic cancer cells proliferation in vitro and in vivo via blocking EGFR/Akt pathway. Co-author DOI 10.1002/cbin.11866↗
  2. Scoparone inhibits pancreatic cancer through PI3K/Akt signaling pathway. Co-author DOI 10.4251/wjgo.v13.i9.1164↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jintao Guo · 1 shared paper, 2021 · strength 0.16
  2. Siyu Sun · 1 shared paper, 2021 · strength 0.16
  3. Nan Ge · 1 shared paper, 2021 · strength 0.16
  4. Zeyao Tang · 1 shared paper, 2022 · strength 0.16
  5. Zheng Zhou · 1 shared paper, 2022 · strength 0.16
  6. Peng Chu · 1 shared paper, 2022 · strength 0.16
  7. Zhaolin Sun · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.